デフォルト表紙
市場調査レポート
商品コード
1434974

抗精神病薬市場:クラス別、適応症別-2024~2030年の世界予測

Antipsychotic Drugs Market by Class (First Generation, Second Generation, Third Generation), Indication (Bipolar Disorders, Dementia, Schizophrenia) - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 181 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
抗精神病薬市場:クラス別、適応症別-2024~2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗精神病薬市場規模は2023年に96億5,000万米ドルと推計され、2024年には104億2,000万米ドルに達し、CAGR 8.01%で2030年には165億6,000万米ドルに達すると予測されます。

抗精神病薬の世界市場

主な市場の統計
基準年[2023] 96億5,000万米ドル
予測年[2024] 104億2,000万米ドル
予測年 [2030] 165億6,000万米ドル
CAGR(%) 8.01%
抗精神病薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗精神病薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、抗精神病薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-抗精神病薬市場の市場規模および予測は?

2-抗精神病薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-抗精神病薬市場における技術動向と規制の枠組みは?

4-抗精神病薬市場における主要ベンダーの市場シェアは?

5-抗精神病薬市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 精神病および関連疾患の有病率の増加
      • 政府からの医薬品承認の増加
      • メンタルヘルスとウェルネスに対する意識の高まり
    • 抑制要因
      • 老舗ブランドの特許切れ
    • 機会
      • 新しい抗精神病薬の研究開発と臨床試験
      • 抗精神病薬検査の改善
    • 課題
      • 厳格な規制枠組みとコンプライアンス
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗精神病薬市場:クラス別

  • 初代
    • ハルド
    • ナバネ
  • 第2世代
    • ジオドン
    • インヴェガ
    • ラトゥーダ
    • リスパダール
    • セロクエル
    • ジプレキサ
  • 第三世代
    • エビリファイ

第7章 抗精神病薬市場適応症別

  • 双極性障害
  • 認知症
  • 統合失調症
  • 単極性うつ病

第8章 南北アメリカの抗精神病薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の抗精神病薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの抗精神病薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Alkermes, Inc.
    • AMBOSS GmbH
    • Amgen Inc
    • Arlak Biotech
    • AstraZeneca PLC
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Dr. Reddy's Laboratories, Ltd.
    • Eli Lilly and Company
    • Flagship Biotech International Pvt. Ltd.
    • GlaxoSmithKline PLC
    • H. Lundbeck A/S
    • Johnson & Johnson Services Inc.
    • Lifecare Neuro Products Ltd.
    • Luye Pharma Group
    • Merck & Co., Inc.
    • Novartis AG
    • Otsuka Pharmaceutical Co. Ltd.
    • Pfizer, Inc.
    • S. Karger AG
    • Seqirus Pty Ltd
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Teva Pharmaceutical Industries, Ltd.
    • Vanda Pharmaceuticals Inc.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTIPSYCHOTIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIPSYCHOTIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIPSYCHOTIC DRUGS MARKET DYNAMICS
  • FIGURE 7. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 8. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIPSYCHOTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALDO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY NAVANE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GEODON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INVEGA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LATUDA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERDAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SEROQUEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ZYPREXA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ABILIFY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY UNIPOLAR DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 236. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. ANTIPSYCHOTIC DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-AD36CD897CF3

[181 Pages Report] The Antipsychotic Drugs Market size was estimated at USD 9.65 billion in 2023 and expected to reach USD 10.42 billion in 2024, at a CAGR 8.01% to reach USD 16.56 billion by 2030.

Global Antipsychotic Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 9.65 billion
Estimated Year [2024] USD 10.42 billion
Forecast Year [2030] USD 16.56 billion
CAGR (%) 8.01%
Antipsychotic Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antipsychotic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antipsychotic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antipsychotic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes, Inc., AMBOSS GmbH, Amgen Inc, Arlak Biotech, AstraZeneca PLC, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Company, Flagship Biotech International Pvt. Ltd., GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Services Inc., Lifecare Neuro Products Ltd., Luye Pharma Group, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer, Inc., S. Karger AG, Seqirus Pty Ltd, Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries, Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Antipsychotic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Class
    • First Generation
      • Haldo
      • Navane
    • Second Generation
      • Geodon
      • Invega
      • Latuda
      • Risperdal
      • Seroquel
      • Zyprexa
    • Third Generation
      • Abilify
  • Indication
    • Bipolar Disorders
    • Dementia
    • Schizophrenia
    • Unipolar Depression
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antipsychotic Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antipsychotic Drugs Market?

3. What are the technology trends and regulatory frameworks in the Antipsychotic Drugs Market?

4. What is the market share of the leading vendors in the Antipsychotic Drugs Market?

5. Which modes and strategic moves are suitable for entering the Antipsychotic Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antipsychotic Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of psychosis and associated diseases
      • 5.1.1.2. Rising drug approval from governments
      • 5.1.1.3. Growing awareness regarding mental health and wellness
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiry of established brands
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D and clinical trials for new antipsychotic drugs
      • 5.1.3.2. Improvements in antipsychotic drug testing
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework and compliance
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antipsychotic Drugs Market, by Class

  • 6.1. Introduction
  • 6.2. First Generation
    • 6.3.1. Haldo
    • 6.3.2. Navane
  • 6.3. Second Generation
    • 6.4.1. Geodon
    • 6.4.2. Invega
    • 6.4.3. Latuda
    • 6.4.4. Risperdal
    • 6.4.5. Seroquel
    • 6.4.6. Zyprexa
  • 6.4. Third Generation
    • 6.5.1. Abilify

7. Antipsychotic Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Bipolar Disorders
  • 7.3. Dementia
  • 7.4. Schizophrenia
  • 7.5. Unipolar Depression

8. Americas Antipsychotic Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Antipsychotic Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Antipsychotic Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbbVie Inc.
    • 12.1.2. Alkermes, Inc.
    • 12.1.3. AMBOSS GmbH
    • 12.1.4. Amgen Inc
    • 12.1.5. Arlak Biotech
    • 12.1.6. AstraZeneca PLC
    • 12.1.7. Bristol-Myers Squibb Company
    • 12.1.8. Daiichi Sankyo Company, Limited
    • 12.1.9. Dr. Reddy's Laboratories, Ltd.
    • 12.1.10. Eli Lilly and Company
    • 12.1.11. Flagship Biotech International Pvt. Ltd.
    • 12.1.12. GlaxoSmithKline PLC
    • 12.1.13. H. Lundbeck A/S
    • 12.1.14. Johnson & Johnson Services Inc.
    • 12.1.15. Lifecare Neuro Products Ltd.
    • 12.1.16. Luye Pharma Group
    • 12.1.17. Merck & Co., Inc.
    • 12.1.18. Novartis AG
    • 12.1.19. Otsuka Pharmaceutical Co. Ltd.
    • 12.1.20. Pfizer, Inc.
    • 12.1.21. S. Karger AG
    • 12.1.22. Seqirus Pty Ltd
    • 12.1.23. Sumitomo Dainippon Pharma Co., Ltd.
    • 12.1.24. Teva Pharmaceutical Industries, Ltd.
    • 12.1.25. Vanda Pharmaceuticals Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing